CBD Oil and Medical Marijuana
Cannabis has been used in a variety of ways for thousands of years and used for its potential therapeutic properties for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD).
Although more research is needed, there are still studies being conducted to prove that cannabis can be therapy for IBD.
Cannabis for IBD
Some people with IBD use cannabis as a complementary treatment option with their other medications if they are unable to help them with their mood, pain, nausea or lack of appetite, as cannabis does.
Some people with IBD turn to complementary and alternatives like medical marijuana because it gives them a sense of control over their disease, by giving them something to fight their symptoms. Others feel that options like medical marijuana may have fewer side effects than other treatments.
Cannabinoids are the active compounds in the cannabis plant and there are two more well-known cannabinoids, THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol). THC can help with the reduction of nausea and pain, increased appetite, psychological effects of euphoria and altered sensory perception, bringing a high.
CBD does not cause intoxicating effects, but more sedative effects that can help reduce convulsions, nausea, and inflammation. CBD contains little to no THC but a lot of people who use medical marijuana may use a varying of each.
How It Works
Researchers have discovered that the human body has an endocannabinoid system (ECS), which is distributed throughout the body and plays a part in improving many functions, including pain, mood, appetite, and the movement of the gastrointestinal system. The ECS is comprised of the cannabinoids the body produces, the receptors they act on, and the enzymes involved. The ECS receptors are cannabinoid 1 and 2 (CB1 and CB2), and both CB1 and CB2 are found in all layers of the intestines. THC and CBD have similar shapes to the internal cannabinoids and work on the same receptors.
1. Schicho, Rudolf, and Martin Storr. “Cannabis Finds Its Way into Treatment of Crohn's Disease.” Pharmacology, vol. 93, no. 1-2, 2014, pp. 1–3., doi:10.1159/000356512.
2. Durst, Ronen, et al. “Cannabidiol, a Nonpsychoactive Cannabis Constituent, Protects against Myocardial Ischemic Reperfusion Injury.” American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 6, 2007, doi:10.1152/ajpheart.00098.2007.
3. Iseger, Tabitha A., and Matthijs G. Bossong. “A Systematic Review of the Antipsychotic Properties of Cannabidiol in Humans.” Schizophrenia Research, vol. 162, no. 1-3, 2015, pp. 153–161., doi:10.1016/j.schres.2015.01.033.
4. Iffland, Kerstin, and Franjo Grotenhermen. “An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.” Cannabis and Cannabinoid Research, vol. 2, no. 1, 2017, pp. 139–154., doi:10.1089/can.2016.0034.
5. Blessing, Esther M., et al. “Cannabidiol as a Potential Treatment for Anxiety Disorders.” Neurotherapeutics, vol. 12, no. 4, 2015, pp. 825–836., doi:10.1007/s13311-015-0387-1.